Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

Reiss, Theodore F; Hill, James B.; Harman, Eloise; Ji Zhang; Tanaka, Wesley K.; Bronsky, Edwin; Guerreiro, Debra; Hendeles, Leslie; Reiss, T F; Hill, J B; Harman, E; Zhang, J; Tanaka, W K; Bronsky, E; Guerreiro, D; Hendeles, L
December 1997
Thorax;Dec1997, Vol. 52 Issue 12, p1030
Academic Journal
journal article
No abstract available.


Related Articles

  • EFFICACY OF ANTILEUKOTRIENE THERAPY IN EXERCISE-INDUCED BRONCHOSPASM IN SKIERS AND BIATHLONISTS. Nikitina, L. Y.; Soodaeva, S. K.; Kotlyarova, V. N.; Petrovskaya, Y. A.; Shashkova, T. V.; Gasymova, S. Sh.; Petrovsky, F. I. // Medical Technologies in Medicine / Sovremennye Tehnologii v Medi;2014, Vol. 6 Issue 4, p134 

    Though the evidence base on application of antileukotrienesin asthmatic patients with exercise-induced bronchoconstriction is plentiful, their efficacy in preventing of exercise-induced bronchospasm (EIB) in winter sports athletes without asthma remains insufficiently studied. The aim of the...

  • RoIe of cysteinyl leukotrienes in adenosine 5' -monophosphate induced bronchoconstriction in asthma. Rorke, S.; Jennison, S.; Jeffs, J. A.; Sampson, A. P.; Arshad, H.; Holgate, S. T. // Thorax;Apr2002, Vol. 57 Issue 4, p323 

    Background: Adenosine induced bronchoconstriction in patients with asthma is thought to be mediated by the synthesis and release of autacoids from airway mast cells. In vitro, adenosine induced constriction of asthmatic bronchi is blocked by a combination of specific histamine and cysteinyl...

  • Increased urinary leukotriene E4 during febrile attacks in the hyperimmunoglobulinaemia D and periodic fever syndrome. Frerikel, J.; Willemsen, M. A. A. P.; Weemaes, C. M. R.; Dorland, L.; Mayatepek, E. // Archives of Disease in Childhood;Aug2001, Vol. 85 Issue 2, p158 

    Background-Thehyperimmunoglobulinaemia D and periodic fever syndrome is a hereditary periodic fever, caused by deficiency of the enzyme mevalonate kinase. It is unclear how this defect leads to recurrent fever episodes. Aim-To assess the involvement of cysteinyl leukotrienes in the pathogenesis...

  • Defining the role of antileukotriene agents in the management of asthma. Johnson, Margaret M. // Formulary;Jan2000, Vol. 35 Issue 1, p38 

    The newest class of asthma medications to be marketed in the United States are the antileukotriene agents (ALAs). They include one 5-lipoxygenase inhibitor, zileuton, and two leukotriene receptor antagonists, zafirlukast and montelukast. By inhibiting the formation of cysteinyl leukotrienes or...

  • Montelukast, A Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction. Lampe, John B.; McDowell, Karen M. // Clinical Pediatrics;Jan1999, Vol. 38 Issue 1, p60 

    Presents information on a study which examines montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Methodology of the study; Results and discussion on the study; Comment on the study.

  • Cysteinyl Leukotrienes Enhance the Degranulation of Bone Marrow-Derived Mast Cells through the Autocrine Mechanism. Kaneko, Izumi; Suzuki, Kaori; Matsuo, Kaori; Kumagai, Hiroyuki; Owada, Yuji; Noguchi, Naoya; Hishinuma, Takanori; Ono, Masao // Tohoku Journal of Experimental Medicine;Mar2009, Vol. 217 Issue 3, p185 

    The cysteinyl leukotrienes (LTs), LTC4, LTD4, and LTE4, are potent inflammatory mediators and are involved in allergic reactions, such as bronchoconstriction, eosinophilic inflammation, and allergic cell proliferation. The present study aimed to elucidate the role of constitutively produced...

  • Montelukast.  // AHFS Consumer Medication Information;Oct2017, p1 

    Montelukast is used to prevent difficulty breathing, chest tightness, wheezing and coughing caused by asthma. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise. Montelukast is also used to treat the symptoms of seasonal (occurs only at certain times of the...

  • Montelukast: A Review of its Therapeutic Potential in Asthma in Children 2 to 14 Years of Age. Muijsers, R.B.R.; Noble, S. // Pediatric Drugs;2002, Vol. 4 Issue 2, p123 

    Montelukast is a cysteinyl leukotriene receptor antagonist which is used as a preventive treatment for persistent asthma in patients ≥2 years of age. In children aged 6 to 14 years montelukast (5 mg/day) treatment resulted in a significant increase in FEV (forced expiratory volume in 1...

  • Update on the use of montelukast in pediatric asthma. Capristo, Carlo; Rigotti, Erika; Boner, Attilio L. // Allergy & Asthma Proceedings;Jul/Aug2006, Vol. 27 Issue 4, p312 

    Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt...

  • Efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses. Kolm, G.; Zappe, H.; Schmid, R.; Riedelberger, K.; Van Den Hoven, R. // Veterinary Record: Journal of the British Veterinary Association;6/28/2003, Vol. 152 Issue 26, p804 

    Discusses the efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses. Cysteinyl leukotriene receptor antagonist; Treatment dosage; High-performance liquid chromatography with fluorescence detection.


Read the Article


Sign out of this library

Other Topics